Mass tort lawsuit · Checked on November 3, 2026

Dupixent lawsuit (T-cell lymphoma): status November 2026

Yes, the Dupixent lawsuit is active. A new federal MDL, number 3180, had 40 pending Dupixent lawsuits on November 2, 2026. Plaintiffs allege that Dupixent (dupilumab) caused cutaneous T-cell lymphoma (CTCL), including mycosis fungoides. The litigation is at a very early stage.

Key facts from court records
Case	MDL 3180
Court	U.S. District Court, District of New Jersey
Judge	Zahid N. Quraishi
Pending cases	40 (as of November 2, 2026)
Stage	Very early stage; MDL created June 2026
New cases	Law firms are filing new cases
Next scheduled date	None announced in the records we checked
Last checked	November 3, 2026

Pending cases by JPML report date. All case counts and CSV

What plaintiffs allege

Plaintiffs allege that Regeneron and Sanofi failed to warn that Dupixent could cause or unmask cutaneous T-cell lymphoma. The companies deny the claims.

Where the case stands

The MDL was created in June 2026 and is before Judge Zahid N. Quraishi in New Jersey (verified, JPML report; creation date reported).
The court held its initial case management conference on October 1, 2026 (reported).

Settlement status

No settlement had been announced as of November 3, 2026. We report a settlement only when a court order, a company filing or a company statement confirms it, and we never estimate payment amounts.

Updates

Newest first. Each entry says whether we read the record ourselves (verified) or it comes from coverage (reported).

November 2026: The federal panel's report of November 2, 2026 listed 40 pending cases (verified, JPML report).
October 2026: The court held its initial case management conference on October 1 (reported).
October 2026: The federal panel's report of October 1, 2026 listed 38 pending cases (verified, JPML report).
June 2026: The federal panel created MDL 3180 in New Jersey (reported).

What law firms commonly ask callers

Law firms reviewing these cases usually ask about the following. This is general information, not an assessment of any claim:

what Dupixent was prescribed for and when it started
whether a pathology report confirmed CTCL, mycosis fungoides or Sezary syndrome
the diagnosis date

Questions

Is the Dupixent lawsuit real?

Yes. The U.S. Judicial Panel on Multidistrict Litigation listed 40 pending cases in MDL 3180 as of November 2, 2026 (verified). A pending case is a claim filed in court, not a finding that the claim is true.

When will the Dupixent lawsuit settle?

Nobody can predict when or whether a mass tort will settle. What has been disclosed so far: No settlement had been announced as of November 3, 2026. We report a settlement only when a court order, a company filing or a company statement confirms it, and we never estimate payment amounts.

Can Dupixent cause cancer?

That is what the lawsuits allege, and the companies deny it. No court has made a final decision on that question. For medical questions, talk to your doctor.

What is CTCL?

Cutaneous T-cell lymphoma is a rare cancer of white blood cells that first shows up in the skin. Mycosis fungoides is its most common form.

Sources

Verified means we read the court, agency or company record ourselves on the check date. Reported means the fact comes from news or law firm coverage and could not be confirmed on a primary record.